Navigation Links
Device May Offer Alternative to Warfarin for Arrhythmia
Date:8/14/2009

Implantation in people at risk for stroke could reduce medication use, study suggests

FRIDAY, Aug. 14 (HealthDay News) -- Closing the heart's left atrial appendage could offer an alternative to long-term warfarin treatment for people with non-valvular atrial fibrillation who are at risk for stroke, according to a new study.

Atrial fibrillation, the most common type of irregular heartbeat, causes the upper chambers of the heart to quiver. This can cause blood to pool and form clots in the left atrial appendage (LAA), a long, tubular structure connected to the left atrial cavity. More than 90 percent of atrial blood clots in people with non-valvular atrial fibrillation may originate in the LAA, according to background information in the study.

The study included 463 people who underwent percutaneous implantation of a device, known as the Watchman, to close off the LAA. Their outcomes were compared with those of 244 people who continued long-term treatment with warfarin.

The researchers determined the effectiveness of the treatments by assessing the occurrence, during an average follow-up of 18 months, of strokes, death from cardiovascular causes and systemic embolisms (blood clots that go somewhere other than the brain). They also totaled the occurrence of such serious problems as major bleeding, pericardial effusion (accidental puncture of the heart causing fluid collection in the heart sac) and clots caused by the implanted device.

After 1,065 patient-years of follow-up, there were 3.0 such occurrences per 100 patient-years among those who'd had the device implanted, compared with 4.9 in the warfarin group, for a risk reduction of 38 percent. But people in the device group had more serious safety events -- 7.4 events per 100 patient-years versus 4.4 events in the warfarin group, the researchers found.

"The efficacy of percutaneous closure of the LAA with this device was non-inferior to that of warfarin therapy," concluded Dr. David R. Holmes, of the Mayo Clinic in Rochester, Minn., and his colleagues. "Although there was a higher rate of adverse safety events in the intervention group than the control group, events in the intervention group were mainly a result of periprocedural complications," they wrote.

"Closure of the LAA might provide an alternative strategy to chronic warfarin therapy for stroke prophylaxis in patients with non-valvular atrial fibrillation," they added.

The study appears this week in The Lancet.

More information

The American Academy of Family Physicians has more about atrial fibrillation.



-- Robert Preidt



SOURCE: The Lancet, news release, Aug. 13, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Nfocus Neuromedical Obtains CE Approval for New Vascular Reconstruction Device
2. Worlds First Emergency Medical Device Franchise Launches eMed-Alert
3. BrainScope(TM) Receives FDA Clearance for Portable EEG Device
4. Inaugural Medical Device Connectivity Conference & Exhibition to Focus on Connecting Medical Devices to People, Workflow and Information Systems
5. X4 Labs to Create Solid Gold Male Enhancement Device for Rich Saudi Man
6. ThermoGenesis Announces Launch of Res-Q System; New Device Expands Companys Presence in Bone Marrow Sector
7. ReGen Biologics Clarifies Recent Press about the Menaflex Device
8. Validation & Compliance Institute, LLC, to Provide Medical Device Regulatory Training for the University of Michigans Medical Innovation Center
9. New Surgical Device Revolutionizes Face Lifts, Abdominoplasty and Breast Reduction Surgery Promising Patients Quicker Recovery Time, Less Pain and Fewer Bruises
10. CVS/pharmacy Enhancing Accessibility for the Visually Impaired To Its Web Site and Store Point of Sales Devices
11. Valve Repair First in New England Done With Robotic Device
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Device May Offer Alternative to Warfarin for Arrhythmia
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... DDS, and Randall Markarian, DDS, are co-chairs for the Illinois State Dental Society ... Friday-Saturday, July 15-16 at the Gateway Convention Center in Collinsville. , ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... Foundation, a not-for-profit organization responsible for clinical transfusion research programs and for the ... the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) study. , ...
(Date:6/23/2016)... ... June 23, 2016 , ... SyncDog, Inc. ... mobile security software, is featured in the current issue of Silicon Review ... companies with innovative technology solutions and features them in their magazine. The magazine ...
(Date:6/23/2016)... Newark, NJ (PRWEB) , ... June 23, 2016 ... ... declared today’s Appellate Court ruling a victory for consumers seeking relief from the ... Div., Docket No. A2913-15T2 & A2929-15T2. , In their ruling ( ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... A key ... DC area, which is one of the best known examples of areas that lack ... amassed almost a thousand daily users. , Any participant within the marijuana industry, ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Consumers have taken a more ... placed more emphasis on patient outcomes. ... in the pharmaceutical industry have evolved beyond just ... companies are focusing on becoming more patient-oriented across ... and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, Inc., ... development and manufacturing of collagen and mineral based ... today that Bill Messer has joined ... to further leverage the growing portfolio of oral ... Bill joins the Collagen Matrix executive ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
Breaking Medicine Technology: